23+ hour, 15+ min ago   (261+ words) insitro, the AI therapeutics company built on causal biology, has announced the acquisition of CombinAbleAI alongside the launch of its new TherML" (Therapeutic Machine Learning) platform. The deal, expected to close in late January 2026, marks a significant expansion of insitro's…...

4+ day, 1+ hour ago   (559+ words) Automation in 2026 is no longer judged by the volume of experiments, but by the reliability of the evidence they produce. As complex biology and tighter budgets collide, industry leaders are pivoting toward automated workflows to secure the data integrity required…...

1+ week, 4+ hour ago   (643+ words) Variant Bio, a genomics-driven AI drug discovery company, have announced Inference, the world's first agentic genomic drug discovery platform. Developed over seven years with more than $100 million invested in data and infrastructure, Inference is designed to transform how pharmaceutical R…...

1+ week, 23+ hour ago   (342+ words) Headlamp Health has launched Lumos AI, a new decision-support platform designed to bring greater precision to neuroscience drug development. Headlamp Health has announced the launch of Lumos AI, a comprehensive, intelligent platform designed to help drug developers navigate the biological…...

1+ week, 2+ day ago   (1536+ words) What happens when AI stops guessing and starts reasoning? Agentic AI is bringing scientific logic into the heart of drug discovery. Artificial intelligence is now a routine presence in biomedical research, from literature mining to image analysis. Yet most systems…...

1+ mon, 3+ hour ago   (627+ words) AI in drug discovery is evolving fast. Join the experts behind today's real progress as they share what works, what doesn't and what you need to know next. Attendees will gain practical insight into current capability, the gaps that still…...

1+ mon, 7+ hour ago   (558+ words) Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new opportunities for drug discovery. Scientists at the Icahn School of…...

1+ mon, 1+ week ago   (419+ words) Researchers at LMU Munich have developed Bits2Bonds, the first platform to fuse molecular simulations with machine learning " accelerating the discovery of polymer carriers for therapeutic RNA. Developing effective delivery vehicles for therapeutic RNA is one of the main challenges in modern…...

1+ mon, 1+ week ago   (407+ words) Research to date indicates that CBLB is highly expressed across multiple immune cell subsets and in a wide range of cancers. These findings make CBLB an extremely promising immunotherapy target with strong clinical potential. Insilico describes ISM3830 as a potential best-in-class,…...

1+ mon, 2+ week ago   (1408+ words) Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies. Advances in genomics have transformed the study of disease biology, but many complex and common…...